CHF10196 tablets (florensocatib)

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

27 competitors in Bronchiectasis

#DrugCompanyPhaseTrials

1

Theo-Dur

Pfizer

Approved

22

Cipro

Bayer

Approved

13

Tobrex

VViatris Specialty LLC

Approved

24

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

25

Sporanox

SSebela Pharmaceuticals Development LLC

Approved

26

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

17

Merrem

BB. Braun Medical Inc.

Approved

18

Garamycin

SSchering-Plough

Approved

19

Foradil

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—10

Qvar

SSchering-Plough

Approved

—Show 13 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Bronchiectasis1 trial

A Phase III, Randomised, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Treatment With CHF10196 Tablets (Florensocatib) Compared With Placebo for up to 78 Weeks, Followed by an Open-label Extension, in Male and Female Participants 12 to 85 Years of Age With Bronchiectasis

Not yet recruiting·Chiesi Farmaceutici S.p.A.·Phase 3·NCT07577804·904 enrolled

Details

Drug Info

Related News